Navigation Links
Genetic analysis may predict risk of invasive bladder cancer
Date:4/20/2009

DENVER Genetic variations in the inflammation pathway may predict who would respond to Bacillus-Calmette-Guerin (BCG) treatment and who might experience a recurrence among patients with non-muscle invasive bladder cancer, according to data presented at the American Association for Cancer Research 100th Annual Meeting 2009.

"Our goal is to use genetic information like this to create a genetic blueprint for this disease, which currently recurs in about 70 percent of patients despite initial successful therapy," said Xifeng Wu, M.D., Ph.D., senior author of the study and a professor in the department of epidemiology at the University of Texas M.D. Anderson Cancer Center, where the research was conducted.

Hushan Yang, Ph.D., a postdoctoral fellow at M. D. Anderson and the first author of this study, and colleagues evaluated a panel of 59 single nucleotide polymorphisms in 35 major inflammation genes in all participants that had been treated with BCG therapy, the current treatment standard for non-muscle invasive bladder cancer.

If a patient had a genotype containing the variant allele of the iNOS gene, there was a significant reduction in the risk of recurrence compared with those patients who did not have this variance.

"Survival associated with this variance was 96.7 months compared with 47.0 months among patients with the wild-type gene," Yang said.

In a further analysis, Yang and colleagues calculated a variance combination to identify those patients at high risk for recurrence. The overall median recurrence-free survival time in this group was only 13.5 months compared with more than 96.7 months, or indefinitely, in the low-risk group.

"These genes can be measured through simple blood tests," said Wu. "Once we identify the patients at high risk for recurrence we can adjust their therapy and followup accordingly."


'/>"/>

Contact: Jeremy Moore
Jeremy.moore@aacr.org
267-646-0557
American Association for Cancer Research
Source:Eurekalert

Page: 1

Related medicine news :

1. Many Parents Share Genetic Test Findings With Kids
2. Genetic predisposition increases childhood asthma risk
3. New Alzheimers findings: High stress and genetic risk factor lead to increased memory decline
4. Test Spots Genetic Damage Done by Smoking
5. Scientists demonstate link between genetic variant and effectiveness of smoking cessation meds
6. Scientists highlight benefits of genetic research in sport, but warn of ethical concerns
7. Genetics Hold Promise, Challenges for Cancer Care
8. Researchers genetically engineer micro-organisms into tiny factories
9. Study Questions Genetic Screening for Treatable Diseases
10. Researchers provide genetic associations from a genome-wide scan for cardiovascular disease traits
11. Genetic variation affects smoking cessation treatment
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/14/2014)... In a UT Dallas study involving serious youth offenders, the ... for the next seven years: "How long do you think ... the future encourages offending over time., Author Dr. Alex Piquero ... long life ahead of them offend at very high rates ... going to die much later in life offend much less., ...
(Date:4/14/2014)... Ohio A new study identifies a molecule that ... suggests that the molecule could be an important target ... tumor progression. , The study of microRNA-135b (miR-135b) in ... the journal Cancer Cell and was led ... Center Arthur G. James Cancer Hospital and Richard ...
(Date:4/14/2014)... with symptoms increasing dramatically during some of the most important ... has found. , Depressive symptoms increased on average by 68 ... young men, who were around 25 years old when they ... their children. The results of the study were published April ... is the first to identify when young fathers are at ...
(Date:4/14/2014)... WASHINGTON, April 14In dense, urban centers around the world, ... streets surrounded by tall buildings that block sunlight. And ... are jammed closer together, the darkness will only spread. ... developed a corrugated, translucent panel that redirects sunlight onto ... rooftops and hung over the edge at an angle, ...
(Date:4/14/2014)... aren,t breastfed or not breastfed for long are ... related health problems later in life, according to ... to hypothesize that breastfeeding was important to influencing ... (Northwestern University), a CIFAR (Canadian Institute for Advanced ... program. "It changes the microbiome. It promotes development ...
Breaking Medicine News(10 mins):Health News:UT Dallas study: Youth who fail to envision future commit more crimes 2Health News:Study identifies a likely key driver of colorectal cancer development and progression 2Health News:Young dads at high risk of depression, too 2Health News:Let the sun shine in: Redirecting sunlight to urban alleyways 2Health News:Low birth weight, less breastfeeding create later health risks 2
... YORK, March 7 The following statement is,from Hughes ... Cotlar, LLP:, United States District Judge Eldon E. ... and Deputy Special Masters who will decide,any appeals taken ... resolution program for Vioxx product liability litigation in the,United ...
... has named 13 translational researchers as the 2008 ... Research. The awards, which provide $150,000 per ... support established, independent physician-scientists who are dedicated to ... patient treatmentand mentoring physician-scientist trainees. , The ...
... March 7 Duane Reade Holdings, Inc. today,announced that ... fourth,quarter and full year 2007 financial results before the ... release, the Company will hold a conference,call on Thursday, ... Interim Chief Executive Officer and Chief Marketing Officer, and,John ...
... Tenn., March 7 HCA Inc. announced today the,final results ... million of,its debt securities specified in the table below. The ... 6, 2008. The tender offer was,made on the terms and ... dated February 7, 2008 and the related Letter of Transmittal., ...
... UC Irvine researchers have discovered a dramatically improved method ... easier for scientists to study and potentially treat thousands ... and diabetes. , The technique for the first time ... rates and increase the efficiency of inserting DNA into ...
... TEMECULA, Calif., March 7 Raintree Systems, ... practice management,and electronic medical records solutions, releases ... medical record product for,Bariatric Surgery., The ... for a,single center and enterprise-level implementations; thus ...
Cached Medicine News:Health News:Special Masters Appointed in Program to Resolve U.S. VIOXX(R) Product Liability Lawsuits 2Health News:Special Masters Appointed in Program to Resolve U.S. VIOXX(R) Product Liability Lawsuits 3Health News:Special Masters Appointed in Program to Resolve U.S. VIOXX(R) Product Liability Lawsuits 4Health News:Burroughs Wellcome Fund grants $9.75 million towards translational researchers 2Health News:HCA Announces Final Results for its Debt Tender Offer 2Health News:HCA Announces Final Results for its Debt Tender Offer 3Health News:HCA Announces Final Results for its Debt Tender Offer 4Health News:New stem cell technique improves genetic alteration 2Health News:New stem cell technique improves genetic alteration 3Health News:Raintree Systems Launches the First Integrated Practice Management and Electronic Medical Records Application Within the Bariatric Surgery Industry 2
(Date:1/15/2014)... 2014  Novation, the leading health care supply ... new IT value-added reseller (VAR) national contracts that ... IT goods and services at lower costs. These ... as value-added services such as initiative assistance and ... Novation agreements were awarded to CDW Government, Paragon ...
(Date:1/15/2014)... 15, 2014  Humberto C. Antunes,  Galderma  worldwide CEO, ... the Journal of Drugs in Dermatology (JDD) ... (ODAC). The event is January 17-20, 2014, at the Omni Orlando ... The ODAC is a distinguished event ... dermatology for clinical and aesthetic dermatology practitioners in the ...
(Date:1/15/2014)... Jan. 15, 2014 Tegra Medical is very ... Mark King as its new Chief Executive Officer.  ... Operating Officer, in which he has overseen the company,s ... Mississippi , and Costa Rica.  Mr. King ... broad-based operations, sales, engineering and manufacturing experience in medical ...
Breaking Medicine Technology:New Novation Information Technology VAR Contracts Offer Significant Savings to Hospitals 2Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 2Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 3Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 4Tegra Medical Appoints New Chief Executive Officer 2Tegra Medical Appoints New Chief Executive Officer 3
... With 30 Installed Inveon Imaging Systems, Siemens ... Position in Preclinical Imaging Centers, HOFFMAN ... adage,says "a picture is worth 1,000 words," ... research where high-resolution images can validate years ...
... Results Seen Since Presentation ... to Include Alvespimycin Plus Trastuzumab Plus ... Paclitaxel Regimen, HAYWARD, ... data from a Phase 1 clinical,trial showing that alvespimycin, its second-generation Hsp90 ...
Cached Medicine Technology:Siemens Preclinical Imaging System Helps The Methodist Hospital in Houston Further Its Research Mission 2Siemens Preclinical Imaging System Helps The Methodist Hospital in Houston Further Its Research Mission 3Siemens Preclinical Imaging System Helps The Methodist Hospital in Houston Further Its Research Mission 4Siemens Preclinical Imaging System Helps The Methodist Hospital in Houston Further Its Research Mission 5Kosan's Second-Generation Hsp90 Inhibitor, Alvespimycin, Shows 42% Clinical Benefit in Phase 1 HER2-Positive Metastatic Breast Cancer Trial 2Kosan's Second-Generation Hsp90 Inhibitor, Alvespimycin, Shows 42% Clinical Benefit in Phase 1 HER2-Positive Metastatic Breast Cancer Trial 3Kosan's Second-Generation Hsp90 Inhibitor, Alvespimycin, Shows 42% Clinical Benefit in Phase 1 HER2-Positive Metastatic Breast Cancer Trial 4Kosan's Second-Generation Hsp90 Inhibitor, Alvespimycin, Shows 42% Clinical Benefit in Phase 1 HER2-Positive Metastatic Breast Cancer Trial 5
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
Medicine Products: